The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity
- 27 March 2012
- journal article
- Published by Elsevier BV in Toxicology and Applied Pharmacology
- Vol. 261 (1), 66-73
- https://doi.org/10.1016/j.taap.2012.03.012
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Krebshilfe (107361, 109188)
This publication has 37 references indexed in Scilit:
- Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicityCell Death & Disease, 2011
- gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatinNucleic Acids Research, 2008
- Anthracycline Cardiotoxicity: From Bench to BedsideJournal of Clinical Oncology, 2008
- The DNA Damage Response: Ten Years AfterMolecular Cell, 2007
- Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in RatsClinical Cancer Research, 2007
- Successful Mitigation of Delayed Intestinal Radiation Injury Using Pravastatin is not Associated with Acute Injury Improvement or Tumor ProtectionInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicityHuman & Experimental Toxicology, 2007
- Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposideBritish Journal of Pharmacology, 2006
- Hepatotoxicity of ChemotherapyThe Oncologist, 2001
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999